This document provides an overview of the clinical pipeline for drugs treating venous thromboembolism (VTE). It highlights betrixaban, currently in Phase III development by Portola Pharmaceuticals, as a potential new oral anticoagulant for the extended treatment of VTE in acutely ill patients. If approved, betrixaban could become the standard of care for this niche patient group, facing minimal competition from other novel oral anticoagulants. Key advantages include its pharmacokinetic profile, safety, dosing regimen, and the development of andexanet alfa as a potential reversal agent, which may help address physician concerns over the lack of antidotes for this drug class.
Investigated the market for cardiovascular medical devices and clinical research organizations (CROs) to understand what roles play in the development and FDA approval process for therapeutics.
The document summarizes coverage from Meddevicetracker on the recent EuroPCR event, an annual cardiovascular conference. It provides instructions on how to search Meddevicetracker's database to find information on events that occurred at EuroPCR 2016, including an example of results found for a trial on the Lotus heart valve. The database also allows viewing analyses of medical devices and technologies presented, such as a bioresorbable vascular scaffold called Fantom. Users can filter the competitive landscape by product type, with an example given focusing on drug-eluting stents.
The document provides business summaries for three medical device companies: Hansen Medical, which develops robotic catheter systems; ViroPharma, which focuses on drugs for infectious diseases; and Stereotaxis, which designs magnetic navigation systems for cardiac catheters.
This document summarizes a presentation given at the Inaugural Digital Broadcasting Switchover Caribbean conference from August 13-15, 2012 in Antigua and Barbuda. The presentation provided an overview of digital television transition globally, outlining progress in regions such as Europe, Africa, the Middle East, Asia-Pacific, Latin America, North America, and the Caribbean. It discussed lessons learned, emphasizing the importance of regional harmonization, prioritizing consumers, involving stakeholders, and securing necessary funding. The presentation encouraged Caribbean countries to work together to complete digital transitions.
The document discusses enabling telecom companies to deliver accelerated universal services to rural communities. It provides an overview of the African Telecommunications Union (ATU), including its mission to promote ICT development in Africa. It also discusses universal access fund models, highlighting examples from Uganda, South Africa, and Ghana. The roles of governments, regulators, and operators are outlined. The document emphasizes the need for policy and regulatory interventions to incentivize network expansion to rural areas and bridge the access gap.
This document discusses parameters for designing digital television broadcast networks. It covers topics such as calculating transmitter requirements based on field strength, receiver sensitivity and modulation. It also discusses fixed and portable antenna reception considerations. The document compares network designs like single frequency networks (SFN), multi-frequency networks (MFN) and hybrid networks. It provides details on synchronization requirements for SFNs and challenges like interference from mobile networks. The document was presented at the Caribbean Digital Broadcasting Switchover Forum 2012 in Trinidad and Tobago.
Jose Cedeno has over 10 years of experience in computer systems administration and support roles. He has extensive experience administering Unix/Linux systems including Solaris, HP-UX, and Debian. Some of his responsibilities have included managing billing processes, computer security, networking firewalls and VPNs, monitoring systems performance, and applying security policies and standards. He is proficient in programming shell scripts, databases, and various system administration tools.
This document discusses different types of tremors, their clinical manifestations, and examples of diseases they may be associated with. It describes resting tremor, which is abolished with movement and seen in Parkinson's disease. Intentional tremor has consistent amplitude throughout movement with no dysmetria, as seen in essential tremor. Action tremor is present with maintained posture and seen in essential tremor, anxiety, thyrotoxicosis, and medication side effects. Postural tremor develops after a 10 second delay and is seen in Parkinson's disease. Re-emergent tremor is also discussed. The document provides guidance on examining patients for tremor.
Investigated the market for cardiovascular medical devices and clinical research organizations (CROs) to understand what roles play in the development and FDA approval process for therapeutics.
The document summarizes coverage from Meddevicetracker on the recent EuroPCR event, an annual cardiovascular conference. It provides instructions on how to search Meddevicetracker's database to find information on events that occurred at EuroPCR 2016, including an example of results found for a trial on the Lotus heart valve. The database also allows viewing analyses of medical devices and technologies presented, such as a bioresorbable vascular scaffold called Fantom. Users can filter the competitive landscape by product type, with an example given focusing on drug-eluting stents.
The document provides business summaries for three medical device companies: Hansen Medical, which develops robotic catheter systems; ViroPharma, which focuses on drugs for infectious diseases; and Stereotaxis, which designs magnetic navigation systems for cardiac catheters.
This document summarizes a presentation given at the Inaugural Digital Broadcasting Switchover Caribbean conference from August 13-15, 2012 in Antigua and Barbuda. The presentation provided an overview of digital television transition globally, outlining progress in regions such as Europe, Africa, the Middle East, Asia-Pacific, Latin America, North America, and the Caribbean. It discussed lessons learned, emphasizing the importance of regional harmonization, prioritizing consumers, involving stakeholders, and securing necessary funding. The presentation encouraged Caribbean countries to work together to complete digital transitions.
The document discusses enabling telecom companies to deliver accelerated universal services to rural communities. It provides an overview of the African Telecommunications Union (ATU), including its mission to promote ICT development in Africa. It also discusses universal access fund models, highlighting examples from Uganda, South Africa, and Ghana. The roles of governments, regulators, and operators are outlined. The document emphasizes the need for policy and regulatory interventions to incentivize network expansion to rural areas and bridge the access gap.
This document discusses parameters for designing digital television broadcast networks. It covers topics such as calculating transmitter requirements based on field strength, receiver sensitivity and modulation. It also discusses fixed and portable antenna reception considerations. The document compares network designs like single frequency networks (SFN), multi-frequency networks (MFN) and hybrid networks. It provides details on synchronization requirements for SFNs and challenges like interference from mobile networks. The document was presented at the Caribbean Digital Broadcasting Switchover Forum 2012 in Trinidad and Tobago.
Jose Cedeno has over 10 years of experience in computer systems administration and support roles. He has extensive experience administering Unix/Linux systems including Solaris, HP-UX, and Debian. Some of his responsibilities have included managing billing processes, computer security, networking firewalls and VPNs, monitoring systems performance, and applying security policies and standards. He is proficient in programming shell scripts, databases, and various system administration tools.
This document discusses different types of tremors, their clinical manifestations, and examples of diseases they may be associated with. It describes resting tremor, which is abolished with movement and seen in Parkinson's disease. Intentional tremor has consistent amplitude throughout movement with no dysmetria, as seen in essential tremor. Action tremor is present with maintained posture and seen in essential tremor, anxiety, thyrotoxicosis, and medication side effects. Postural tremor develops after a 10 second delay and is seen in Parkinson's disease. Re-emergent tremor is also discussed. The document provides guidance on examining patients for tremor.
This document provides information about brachytherapy treatment for lip cancer. It discusses that lip cancer most commonly affects men over 50 and is usually located on the lower lip. Brachytherapy involves placing radioactive sources inside or near the tumor and is commonly used to treat lip cancers from T1-T3 in size. The document describes the brachytherapy technique which involves inserting applicators such as needles or tubes into the lip under local anesthesia. A dosimetry study is then performed to plan radioactive source placement and treatment times/doses. Brachytherapy allows high dose delivery to the tumor while sparing surrounding healthy tissues.
This document discusses peripheral neuropathy, which refers to diseases that affect nerves outside the brain and spinal cord. It covers the types of peripheral nerves and classifications of neuropathies. Some key causes of peripheral neuropathy discussed include diabetes, nutritional deficiencies like B1/B12 deficiency, alcoholism, infections like HIV and leprosy, and certain drugs. Symptoms, clinical presentations, investigations, and treatment approaches for different types of peripheral neuropathies are also summarized.
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenNBCA
- Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major cause of morbidity and mortality worldwide. It is estimated that there are 900,000 cases of VTE per year in the US.
- Recent clinical trials have found that the direct oral anticoagulants rivaroxaban, apixaban, edoxaban and dabigatran are non-inferior to standard therapy for treating VTE and reduce the risk of recurrence, while having a similar or lower risk of bleeding.
- The EINSTEIN DVT and EINSTEIN PE trials found that rivaroxaban was non-infer
Platelets and thrombin systems work together to form blood clots. Platelets become activated when bleeding occurs and begin sticking together. Activated clotting proteins engage in chemical reactions producing fibrin strands that stick to vessel walls, trapping red blood cells and forming clots. Anticoagulants prevent clotting by inhibiting factors in the coagulation cascade like thrombin and factor Xa. Heparin is a commonly used anticoagulant that activates antithrombin to inhibit coagulation factors. Newer direct thrombin and factor Xa inhibitors offer more consistent anticoagulation than warfarin with less drug interactions and monitoring requirements.
VTE refers to deep vein thrombosis and pulmonary embolism, which share common risk factors and pathophysiology. Risk factors include immobilization, recent surgery or trauma, inherited or acquired hypercoagulable states, and certain medical conditions. Signs and symptoms of DVT include leg pain and swelling, while PE presents with dyspnea, chest pain, and potentially hemodynamic instability in severe cases. Diagnosis involves clinical assessment, imaging like ultrasound or CT, and blood tests like D-dimer and Wells criteria. Treatment consists of anticoagulation with heparins or warfarin to prevent clot extension and recurrence.
EBCTCG METAANALYSIS
INDICATION OF POST OP RADIOTHERAPY
Immobilization devices
Conventional planning
Alignment of the Tangential Beam with the Chest Wall Contour
Doses To Heart & Lung By Tangential Fields
This document discusses venous thromboembolism (VTE) in intensive care medicine. It covers the pathophysiology of thrombosis and pulmonary embolism, diagnostics for pulmonary embolism, and therapeutic approaches to VTE including prophylaxis, anticoagulation therapies, and thrombolytics. It highlights several key risk factors for VTE in critically ill and trauma patients.
Venous thromboembolism, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of preventable hospital deaths. DVT occurs when a blood clot forms in a deep vein, usually in the legs, while PE is a blood clot that has traveled to the lungs. Risk factors include older age, genetic factors, recent surgery or trauma, cancer, and prolonged immobility; diagnosis involves clinical scoring and imaging tests like ultrasound and CT scans; and standard treatment is anticoagulant drugs like warfarin to prevent clot progression and recurrence.
Mobile SDK: Considerations & Best Practices LivePerson
Mobile SDKs are a great way to make your service or API easily consumable by the large number of developers out there looking for state of the art tools to make their apps stand out in the competitive marketplaces, but building a stable, compatible and successful SDK is quite a challenge.
In this talk we the technical and design challenges involved in developing an efficient mobile SDK that is highly compatible with its host mobile app, and the various considerations we took into account and the lessons we’ve learned while designing and building LivePerson’s native mobile SDK.
Update on Management of Triple Negative Breast Cancerspa718
This document provides an update on the management of triple negative breast cancer from Dr. Banu Arun at MD Anderson Cancer Center. It discusses that triple negative breast cancer is a heterogeneous disease comprised of several molecular subtypes with different characteristics and potential treatment targets. Clinical trials exploring chemotherapy regimens, platinum agents, PARP inhibitors, anti-angiogenic drugs, and immunotherapies are summarized. Ongoing research aims to better define the subtypes in order to personalize treatment for triple negative breast cancer patients.
This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects.
http://www.researchmoz.us/diarrhea-pipeline-review-h1-2015-report.html
- The document discusses Sanofi's performance at the Cowen Healthcare Conference on March 12, 2018.
- It highlights Sanofi's building of a leadership position in rare blood disorders through recent acquisitions including Bioverativ and planned acquisition of Ablynx.
- Clinical trial results for investigational drugs like caplacizumab for aTTP and fitusiran for hemophilia are presented as enhancing Sanofi's pipeline.
- Growth of Sanofi's immunology franchise including Dupixent is discussed as an emerging driver of specialty care sales.
- The document presents information on Praluent (alirocumab), the first PCSK9 inhibitor therapy approved in the US for treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL cholesterol.
- Praluent demonstrated robust and durable LDL-C reduction of over 52 weeks in clinical trials in patients on maximally tolerated statin therapy, with 57-83% of patients achieving sufficient LDL-C reduction with the 75 mg starting dose.
- The Committee for Medicinal Products for Human Use adopted a positive opinion for Praluent in Europe, and approval is expected in late September 2015. The OD
Heparin Market PPT 2021-26 | Enhancing Huge Growth and Latest Trends by Top P...IMARC Group
As per the latest report by IMARC Group, the global heparin market size reached reached a value of US$ 6.7 Billion in 2020.
Heparin (C12H19NO20S3) is an anticoagulant (blood thinner) that assists in preventing thromboembolic complications.
This report provides information on the therapeutic development for Coronary Vasospasm, complete with latest updates, and special features on late-stage and discontinued projects.
European pharmacovigilance and clinical trials 2016Harris John
European Pharmacovigilance and Clinical Trials 2016 will provide an opportunity to all its attendees to discuss, share and stay updated with present state of affairs in Pharmacovigilance and clinical trials. It will also allow all its participants to discuss the various developments, challenges faced and innovations in the field. The conference will attempt to explore the reforms required to enhance drug safety and public health. The conference will also provides all its participants an opportunity to network with various pharmaceutical industries; clinical research organizations and PV service providers.
European pharmacovigilance and_clinical_trials_2016Fazmina Fajju
The European Pharmacovigilance & Clinical Trials 2016 offers a one of a kind discussion platform for pharmaceutical experts to debate and discuss the challenges they are facing in Pharmacovigilance and Clinical Trials.
Do not miss out on the chance to acquire first-hand knowledge and experiences from pharmaceutical giants such as AstraZeneca, Merck Sereno, Boehringer Ingelheim, Pfizer, Novo Nordisk, Johnson & Johnson, Novartis and many more on the latest technological advances in data capture and effective feasibility models. We will be addressing topics such as Major challenges faced by EU legislation and Emerging Economies and PV Harmonization, Adverse event reporting and PV & clinical trials, Clinical Trials Signal Detection and many others. Join us and be future ready!
Take advantage to meet the leading experts within the field and discuss the latest challenges all your competitors are facing.
We are looking forward to welcoming you on board in 2016!
Glaukos investor presentation q2 2016 for website 08032016glaukos
Glaukos Corporation is a medical technology company transforming glaucoma treatment. Their solution portfolio includes micro-scale injectable therapies to restore and enhance aqueous outflow including the iStent, iStent Inject, and iStent Supra. Clinical trials show the iStent reduces intraocular pressure and medication use when used with cataract surgery or as a standalone procedure. Glaukos has established global commercial operations and seized the first mover opportunity in key markets since US FDA approval of the iStent.
The global acquired orphan blood diseases therapeutics market size reached US$ 8.12 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 13.34 Billion by 2028, exhibiting a growth rate (CAGR) of 8.30% during 2023-2028.
More Info:- https://www.imarcgroup.com/acquired-orphan-blood-diseases-therapeutics-market
This document provides information about brachytherapy treatment for lip cancer. It discusses that lip cancer most commonly affects men over 50 and is usually located on the lower lip. Brachytherapy involves placing radioactive sources inside or near the tumor and is commonly used to treat lip cancers from T1-T3 in size. The document describes the brachytherapy technique which involves inserting applicators such as needles or tubes into the lip under local anesthesia. A dosimetry study is then performed to plan radioactive source placement and treatment times/doses. Brachytherapy allows high dose delivery to the tumor while sparing surrounding healthy tissues.
This document discusses peripheral neuropathy, which refers to diseases that affect nerves outside the brain and spinal cord. It covers the types of peripheral nerves and classifications of neuropathies. Some key causes of peripheral neuropathy discussed include diabetes, nutritional deficiencies like B1/B12 deficiency, alcoholism, infections like HIV and leprosy, and certain drugs. Symptoms, clinical presentations, investigations, and treatment approaches for different types of peripheral neuropathies are also summarized.
Venous Thromboembolism (VTE): Recent Advances in Reducing the Disease BurdenNBCA
- Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a major cause of morbidity and mortality worldwide. It is estimated that there are 900,000 cases of VTE per year in the US.
- Recent clinical trials have found that the direct oral anticoagulants rivaroxaban, apixaban, edoxaban and dabigatran are non-inferior to standard therapy for treating VTE and reduce the risk of recurrence, while having a similar or lower risk of bleeding.
- The EINSTEIN DVT and EINSTEIN PE trials found that rivaroxaban was non-infer
Platelets and thrombin systems work together to form blood clots. Platelets become activated when bleeding occurs and begin sticking together. Activated clotting proteins engage in chemical reactions producing fibrin strands that stick to vessel walls, trapping red blood cells and forming clots. Anticoagulants prevent clotting by inhibiting factors in the coagulation cascade like thrombin and factor Xa. Heparin is a commonly used anticoagulant that activates antithrombin to inhibit coagulation factors. Newer direct thrombin and factor Xa inhibitors offer more consistent anticoagulation than warfarin with less drug interactions and monitoring requirements.
VTE refers to deep vein thrombosis and pulmonary embolism, which share common risk factors and pathophysiology. Risk factors include immobilization, recent surgery or trauma, inherited or acquired hypercoagulable states, and certain medical conditions. Signs and symptoms of DVT include leg pain and swelling, while PE presents with dyspnea, chest pain, and potentially hemodynamic instability in severe cases. Diagnosis involves clinical assessment, imaging like ultrasound or CT, and blood tests like D-dimer and Wells criteria. Treatment consists of anticoagulation with heparins or warfarin to prevent clot extension and recurrence.
EBCTCG METAANALYSIS
INDICATION OF POST OP RADIOTHERAPY
Immobilization devices
Conventional planning
Alignment of the Tangential Beam with the Chest Wall Contour
Doses To Heart & Lung By Tangential Fields
This document discusses venous thromboembolism (VTE) in intensive care medicine. It covers the pathophysiology of thrombosis and pulmonary embolism, diagnostics for pulmonary embolism, and therapeutic approaches to VTE including prophylaxis, anticoagulation therapies, and thrombolytics. It highlights several key risk factors for VTE in critically ill and trauma patients.
Venous thromboembolism, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of preventable hospital deaths. DVT occurs when a blood clot forms in a deep vein, usually in the legs, while PE is a blood clot that has traveled to the lungs. Risk factors include older age, genetic factors, recent surgery or trauma, cancer, and prolonged immobility; diagnosis involves clinical scoring and imaging tests like ultrasound and CT scans; and standard treatment is anticoagulant drugs like warfarin to prevent clot progression and recurrence.
Mobile SDK: Considerations & Best Practices LivePerson
Mobile SDKs are a great way to make your service or API easily consumable by the large number of developers out there looking for state of the art tools to make their apps stand out in the competitive marketplaces, but building a stable, compatible and successful SDK is quite a challenge.
In this talk we the technical and design challenges involved in developing an efficient mobile SDK that is highly compatible with its host mobile app, and the various considerations we took into account and the lessons we’ve learned while designing and building LivePerson’s native mobile SDK.
Update on Management of Triple Negative Breast Cancerspa718
This document provides an update on the management of triple negative breast cancer from Dr. Banu Arun at MD Anderson Cancer Center. It discusses that triple negative breast cancer is a heterogeneous disease comprised of several molecular subtypes with different characteristics and potential treatment targets. Clinical trials exploring chemotherapy regimens, platinum agents, PARP inhibitors, anti-angiogenic drugs, and immunotherapies are summarized. Ongoing research aims to better define the subtypes in order to personalize treatment for triple negative breast cancer patients.
This report provides comprehensive information on the therapeutic development for Diarrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diarrhea and special features on late-stage and discontinued projects.
http://www.researchmoz.us/diarrhea-pipeline-review-h1-2015-report.html
- The document discusses Sanofi's performance at the Cowen Healthcare Conference on March 12, 2018.
- It highlights Sanofi's building of a leadership position in rare blood disorders through recent acquisitions including Bioverativ and planned acquisition of Ablynx.
- Clinical trial results for investigational drugs like caplacizumab for aTTP and fitusiran for hemophilia are presented as enhancing Sanofi's pipeline.
- Growth of Sanofi's immunology franchise including Dupixent is discussed as an emerging driver of specialty care sales.
- The document presents information on Praluent (alirocumab), the first PCSK9 inhibitor therapy approved in the US for treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL cholesterol.
- Praluent demonstrated robust and durable LDL-C reduction of over 52 weeks in clinical trials in patients on maximally tolerated statin therapy, with 57-83% of patients achieving sufficient LDL-C reduction with the 75 mg starting dose.
- The Committee for Medicinal Products for Human Use adopted a positive opinion for Praluent in Europe, and approval is expected in late September 2015. The OD
Heparin Market PPT 2021-26 | Enhancing Huge Growth and Latest Trends by Top P...IMARC Group
As per the latest report by IMARC Group, the global heparin market size reached reached a value of US$ 6.7 Billion in 2020.
Heparin (C12H19NO20S3) is an anticoagulant (blood thinner) that assists in preventing thromboembolic complications.
This report provides information on the therapeutic development for Coronary Vasospasm, complete with latest updates, and special features on late-stage and discontinued projects.
European pharmacovigilance and clinical trials 2016Harris John
European Pharmacovigilance and Clinical Trials 2016 will provide an opportunity to all its attendees to discuss, share and stay updated with present state of affairs in Pharmacovigilance and clinical trials. It will also allow all its participants to discuss the various developments, challenges faced and innovations in the field. The conference will attempt to explore the reforms required to enhance drug safety and public health. The conference will also provides all its participants an opportunity to network with various pharmaceutical industries; clinical research organizations and PV service providers.
European pharmacovigilance and_clinical_trials_2016Fazmina Fajju
The European Pharmacovigilance & Clinical Trials 2016 offers a one of a kind discussion platform for pharmaceutical experts to debate and discuss the challenges they are facing in Pharmacovigilance and Clinical Trials.
Do not miss out on the chance to acquire first-hand knowledge and experiences from pharmaceutical giants such as AstraZeneca, Merck Sereno, Boehringer Ingelheim, Pfizer, Novo Nordisk, Johnson & Johnson, Novartis and many more on the latest technological advances in data capture and effective feasibility models. We will be addressing topics such as Major challenges faced by EU legislation and Emerging Economies and PV Harmonization, Adverse event reporting and PV & clinical trials, Clinical Trials Signal Detection and many others. Join us and be future ready!
Take advantage to meet the leading experts within the field and discuss the latest challenges all your competitors are facing.
We are looking forward to welcoming you on board in 2016!
Glaukos investor presentation q2 2016 for website 08032016glaukos
Glaukos Corporation is a medical technology company transforming glaucoma treatment. Their solution portfolio includes micro-scale injectable therapies to restore and enhance aqueous outflow including the iStent, iStent Inject, and iStent Supra. Clinical trials show the iStent reduces intraocular pressure and medication use when used with cataract surgery or as a standalone procedure. Glaukos has established global commercial operations and seized the first mover opportunity in key markets since US FDA approval of the iStent.
The global acquired orphan blood diseases therapeutics market size reached US$ 8.12 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 13.34 Billion by 2028, exhibiting a growth rate (CAGR) of 8.30% during 2023-2028.
More Info:- https://www.imarcgroup.com/acquired-orphan-blood-diseases-therapeutics-market
Sandhoff Disease Market 2023: Epidemiology, Industry Trends, Size, Share And ...frankmorgan27
The growing cases of lipid storage disorders owing to the inherited deficiencies in producing functional catabolic enzymes are primarily augmenting the Sandhoff disease market.
Will reimbursement prove to be the biggest barrier as three gene therapies gain regulatory approval?
Datamonitor Healthcare has carried out a comprehensive analysis of gene therapy products in commercial development worldwide based on information derived from Pharmaprojects. The results have been analyzed to reveal trends in gene therapy technologies and approaches to the treatment of different diseases.
The number of gene therapy products in preclinical to Phase III and beyond stages of development doubled between 2012 and 2015. Additionally, three gene therapy products – Glybera (uniQure), Imlygic (Amgen), and Strimvelis (GlaxoSmithKline) – have now received regulatory approval in Europe. While these approvals give some validation to gene therapy as a therapeutic strategy, doubts remain around their return on investment. The high upfront costs and residual uncertainty around the long-term benefits of gene therapy products are proving to be hurdles to wider access and reimbursement, but seem to have had a minimal impact on companies’ appetite to dive into this arena, with cancer and monogenic diseases proving to be the most popular indications for the development of gene therapy products.
For more information on this report visit https://pharmastore.informa.com/product/trends-gene-therapy/
The global acquired orphan blood diseases therapeutics market size reached US$ 8.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/acquired-orphan-blood-diseases-therapeutics-market
MDxHealth provides molecular diagnostic tests to improve diagnosis and treatment decisions for urological cancers like prostate and bladder cancer. Their lead product is ConfirmMDx, which helps determine if a repeat biopsy is needed after an initial negative biopsy result. They are also launching SelectMDx, a urine-based test to improve patient selection for initial biopsies. Looking forward, they plan to expand their product portfolio and commercial footprint in the US and EU to address unmet needs in urological cancer testing and help reduce unnecessary invasive procedures.
The global PAH market is expected to reach $XX billion by 2019, growing at a CAGR of XX% from 2015-2019. Key drivers of growth include the launch of new drugs like Uptravi in 2016 and the increasing popularity of combination therapies. Over the next five years, market revenue is forecast to remain stable due to patent expiries and new drug launches. The report profiles major players like Actelion, United Therapeutics, and SteadyMed and provides an analysis of the PAH market size, trends, opportunities, and competitive landscape.
This document summarizes information from the WHO Drug Information journal regarding increasing access to safe blood products in low and middle income countries. It notes that a large amount of plasma separated from whole blood donations in these countries is currently being discarded due to inadequate quality standards and production processes. The document calls for improving infrastructure, knowledge, and regulatory oversight in blood establishments in these countries in order to strengthen local plasma production capacity and reduce wastage. It also advocates adding whole blood and red blood cells to the WHO Model List of Essential Medicines to encourage investment in building local blood systems.
Non alcoholic steatohepatitis - pipeline review, h1 2014Ambikabasa
This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.
The document provides an overview of the global therapeutic pipeline for Paroxysmal Nocturnal Hemoglobinuria (PNH) as of the first half of 2015. It details over 20 drugs in development for PNH across multiple companies and stages of development. The pipeline is evaluated based on drug targets, mechanisms of action, routes of administration, molecule types, and comparative analyses. Recent clinical trial results and developments are also summarized.
- Sanofi is building a leading rare blood disorder franchise through the acquisitions of Bioverativ and Ablynx which expand their portfolio of therapies for rare diseases like hemophilia and acquired thrombotic thrombocytopenic purpura (aTTP).
- Bioverativ strengthens Sanofi's position in hemophilia with therapies like Eloctate and Alprolix and the investigational fitusiran. Caplacizumab shows strong results for aTTP and was filed for approval in the EU and U.S.
- The global hemophilia market is approximately $10 billion and growing at 7% annually, driven by reliable extended half-life factor therapies and broader
This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and discontinued projects.
http://www.researchmoz.us/rhabdomyosarcoma-pipeline-review-h1-2015-report.html